Johnson & Johnson
JNJHealthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- −95.8%
- Free cash flow
- −21.4%
- Total debt
- −9.16%
Quarter to September 2026, against a year earlier
Follow JNJ
Alert me
Johnson & Johnson (JNJ) EV/EBITDA
As of Nov 19, 2026, Johnson & Johnson (JNJ) trades at a EV/EBITDA of 23.9×. Over the past ten years it has ranged from 9.2× (August 2015) to 25.5× (November 2026); the current reading is higher than 99% of that period. That is above the Drug Manufacturers General industry median of 13.9× and above the Healthcare sector median of 8.5×.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 12.3× | (9.41%) |
| FY2024 | 13.6× | (18.31%) |
| FY2023 | 16.6× | (4.74%) |
| FY2022 | 17.4× | 4.16% |
| FY2021 | 16.7× | (4.60%) |
| FY2020 | 17.5× | 11.65% |
| FY2019 | 15.7× | 17.82% |
| FY2018 | 13.3× | (15.14%) |
| FY2017 | 15.7× | 30.18% |
| FY2016 | 12.1× | 10.03% |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Sep 2026 | 23.7× | 31.68% |
| Jun 2026 | 18.0× | 3.32% |
| Mar 2026 | 17.4× | 41.82% |
| Dec 2025 | 12.3× | 7.50% |
| 43 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| PFE Pfizer Inc. compare | 10.2× |
| AZN AstraZeneca PLC compare | 13.9× |
| NVS Novartis AG compare | 14.6× |
| AMGN Amgen Inc. compare | 16.2× |
| ABBV AbbVie Inc. compare | 19.8× |
| JNJ Johnson & Johnson | 23.9× |
| MRK Merck & Co., Inc. compare | 27.1× |
| LLY Eli Lilly and Company compare | 33.9× |
| GILD Gilead Sciences, Inc. compare | 502× |
| Drug Manufacturers General industry median | 13.9× |
| Healthcare sector median | 8.5× |
| Market median | 10.4× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on JNJ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement